Technology | September 18, 2012

FDA Clears somo•V Automated Breast Ultrasound (ABUS) System

Device approved specifically for screening of women with dense breasts

September 18, 2012 — The U.S. Food and Drug Administration (FDA) has approved U-Systems' somo•v automated breast ultrasound (ABUS) system for breast cancer screening as an adjunct to mammography for asymptomatic women with dense breast tissue. With the approval, the somo•v ABUS system becomes the only device approved specifically for screening women with dense breasts.

“The FDA approval of the somo•v ABUS device is an exciting and important development in the detection of early, curable breast cancer. The use of somo•v for screening women with dense breasts will undoubtedly have a positive impact for women currently being underserved by mammography,” said Rachel Brem, M.D., director of breast imaging at The George Washington University Hospital, Washington, D.C. “Mammography is an effective tool at finding breast cancer, but it doesn’t work equally well in everyone. Recently completed studies demonstrated with the addition of ABUS, we find about 30 percent more cancers in women who have normal mammogram, normal physical examination and dense breasts. For the more than 40 percent of women who have dense breasts, this is a significant advancement in their breast healthcare.”

The approval comes after a Radiological Devices Panel of the FDA’s Medical Devices Advisory Committee unanimously recommended approval of U-Systems’ premarket approval (PMA) application in April. The somo•v system is the only ultrasound device approved for breast cancer screening in the United States, Canada and 27 European Union countries as an adjunct to mammography for asymptomatic women with dense breast tissue.

“Enabling radiologists to use the information obtained from mammography and integrate that with the information obtained with ultrasound, leverages the potential of ABUS in a screening environment to find the 30 percent additional cancers that would not have been found with mammography alone,” said Ron Ho, president and CEO of U-Systems. “Research shows that ABUS can help find cancer in women with dense breasts, and that the cancers are smaller and early stage. With formal approval, we are moving rapidly from development to commercialization and look forward to making the somo•v ABUS system more widely available across the United States.”

Dense breast tissue not only increases the risk of breast cancer up to four to six times, but also makes cancer more difficult to detect using mammography, according to multiple large studies. One study, published in the New England Journal of Medicine, showed 35 percent of breast cancer goes undetected by mammography in women with dense breasts, as density masks the appearance of tumors (Boyd, et al, NEJM 2007:356:227-36M). As breast density goes up, the accuracy of mammograms goes down.

Issues with manual breast ultrasound screenings have been the large amount of time these exams take, the need for a highly qualified sonographer, and the variability in how an exam is conducted and how images are interpretated based on operator experience. ABUS automates the exam, making it much faster and eliminating the variability in image acquisition.

Using technology to automate the ultrasound imaging process, the somo•v ABUS system was developed specifically for the high-volume, breast cancer screening environment. The somo•VIEWer advanced 3-D workstation enables fast, accurate review and archiving of patient exams, optimizing breast ultrasound screening workflow.

For more information: www.u-systems.com

Related Content

VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
Managing Architectural Distortion on Mammography Based on MR Enhancement
News | Mammography | May 15, 2019
High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US)...
Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients
News | MRI Breast | May 09, 2019
When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast...
Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer
News | Artificial Intelligence | May 08, 2019
Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to...
Georgia Becomes 38th State With Breast Density Inform Law
News | Breast Density | May 06, 2019
Georgia Gov. Brian Kemp signed breast density inform bill HB62 into law May 3, 2019. The law, which becomes effective...
American Society of Breast Surgeons Issues Risk-based Screening Mammography Guidelines
News | Mammography | May 03, 2019
The American Society of Breast Surgeons (ASBrS) has released the first screening mammography guidelines based on a...
Hologic Launches Trident HD Specimen Radiography System
Technology | Breast Biopsy Systems | April 26, 2019
Hologic Inc. announced global commercial availability of the Trident HD specimen radiography system. The next-...
California Protons Cancer Therapy Center Begins Breast Cancer Study Enrollment
News | Proton Therapy | April 25, 2019
California Protons Cancer Therapy Center announced two major efforts representing significant steps forward in breast...
Women With Coronary Artery Wall Thickness at Risk for Heart Disease
News | Cardiac Imaging | April 25, 2019
The thickness of the coronary artery wall as measured by magnetic resonance imaging (MRI) is an independent marker for...